Designer probiotics for the prevention and treatment of human diseases

Koon Jiew Chua; Wee Chiew Kwok; Nikhil Aggarwal; Tao Sun; Matthew Wook Chang

doi:10.1016/j.cbpa.2017.04.011

Designer probiotics for the prevention and treatment of human diseases

Curr Opin Chem Biol. 2017 Oct:40:8-16. doi: 10.1016/j.cbpa.2017.04.011. Epub 2017 May 4.

Authors

Koon Jiew Chua¹, Wee Chiew Kwok¹, Nikhil Aggarwal¹, Tao Sun¹, Matthew Wook Chang²

Affiliations

¹ Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore.
² Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore. Electronic address: bchcmw@nus.edu.sg.

PMID: 28478369
DOI: 10.1016/j.cbpa.2017.04.011

Abstract

Various studies have shown the beneficial effects of probiotics in humans. The use of synthetic biology to engineer programmable probiotics that specifically targets cancer, infectious agents, or other metabolic diseases has gained much interest since the last decade. Developments made in synthetic probiotics as therapeutics within the last three years will be discussed in this review.

Publication types

Review

MeSH terms

Animals
Autoimmune Diseases / therapy*
Bacteria / genetics
Communicable Diseases / therapy*
Genetic Engineering / methods
Humans
Hypersensitivity / therapy*
Metabolic Diseases / therapy*
Neoplasms / therapy*
Probiotics / therapeutic use*